All In Biotech

Drug Trial Radar · NCT04886258

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Sep 20, 2021

Primary completion

Dec 14, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.

Conditions

  • Symptomatic Knee Osteoarthritis

Interventions

  • DFV890Drug

    DFV890 was administered orally twice per day, 10 mg during 2 weeks and 25 mg during the next 10 weeks.

  • PlaceboDrug

    Matching Placebo was administered orally twice per day during 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain SubscaleTime frame: Baseline, Week 12

Locations

31 sites in 8 countries. Site status is shown where the registry gives one.

  • ARENSIA Explor Med Res Clinic

    Phoenix, Arizona

  • TriWest Reserach Associates

    El Cajon, California

  • Skylight Health Res Inc Color Spr

    Colorado Springs, Colorado

  • IRIS Research and Development

    Plantation, Florida

  • Conquest Research

    Winter Park, Florida

  • Ctr for Adv Research and Education

    Gainesville, Georgia

  • Northwestern University

    Chicago, Illinois

  • Novartis Investigative Site

    San Miguel de Tucumán, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Miguel, Tucumán Province, Argentina

  • Novartis Investigative Site

    Nový Jičín, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Uherské Hradiště, Czechia

  • Novartis Investigative Site

    Brno, Czech Republic, Czechia

  • Novartis Investigative Site

    Bad Doberan, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Leipzig, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Miskolc, Hungary

  • Novartis Investigative Site

    Veszprém, Hungary

  • Novartis Investigative Site

    Kecskemét, Bács-Kiskun county, Hungary

  • Novartis Investigative Site

    Bucharest, Romania

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, Romania

  • Novartis Investigative Site

    Nové Mesto nad Váhom, Slovakia

  • Novartis Investigative Site

    Piešťany, Slovakia

  • Novartis Investigative Site

    A Coruña, Spain

  • Novartis Investigative Site

    Seville, Spain

  • Novartis Investigative Site

    Sabadell, Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.